Literature DB >> 7109539

Further characterization of amyloid-enhancing factor.

M A Axelrad, R Kisilevsky, J Willmer, S J Chen, M Skinner.   

Abstract

Amyloid-enhancing factor (AEF) is a transferable activity that in CBA/J mice reduces the induction time of splenic amyloid deposition to 48 hours. Azocasein, or AgNo3, can induce AEF in the spleen and liver. In the liver several subcellular organelles possess this activity. This is likely due to AEF's adherent properties. AEF is most effective when given by the intravenous route. After intravenous injection, AEF particulates localize to the perifollicular areas of the spleen and Kuppfer cells in the liver. The effects of AEF administration persist for at least 4 weeks. AEF can be solubilized in 4 M glycerol, is not the amyloid A protein, and is not likely to be the serum amyloid P component. The extract can be fractionated by Sepharose 4B column chromatography. The active component is of high molecular weight, and tentative identification by disc electrophoresis has been made.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7109539

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  61 in total

Review 1.  Amyloidosis and the respiratory tract.

Authors:  J D Gillmore; P N Hawkins
Journal:  Thorax       Date:  1999-05       Impact factor: 9.139

Review 2.  Amyloidosis.

Authors:  M F Khan; R H Falk
Journal:  Postgrad Med J       Date:  2001-11       Impact factor: 2.401

3.  Classical and alternative pathway complement activation are not required for reactive systemic AA amyloid deposition in mice.

Authors:  Winston L Hutchinson; Jeff Herbert; Marina Botto; Mark B Pepys
Journal:  Immunology       Date:  2004-06       Impact factor: 7.397

4.  Amyloid A protein amyloidosis induced in apolipoprotein-E-deficient mice.

Authors:  Y Hoshii; H Kawano; D Cui; T Takeda; T Gondo; M Takahashi; K Kogishi; K Higuchi; T Ishihara
Journal:  Am J Pathol       Date:  1997-10       Impact factor: 4.307

5.  Cellular mechanism of fibril formation from serum amyloid A1 protein.

Authors:  Stephanie Claus; Katrin Meinhardt; Tobias Aumüller; Ioana Puscalau-Girtu; Julia Linder; Christian Haupt; Paul Walther; Tatiana Syrovets; Thomas Simmet; Marcus Fändrich
Journal:  EMBO Rep       Date:  2017-06-21       Impact factor: 8.807

6.  The effects of sodium sulfate, glycosaminoglycans, and Congo red on the structure, stability, and amyloid formation of an immunoglobulin light-chain protein.

Authors:  Richard W McLaughlin; Janelle K De Stigter; Laura A Sikkink; Elizabeth M Baden; Marina Ramirez-Alvarado
Journal:  Protein Sci       Date:  2006-06-02       Impact factor: 6.725

7.  Activities of lysosomal enzymes and levels of serum amyloid A (SAA) in blood plasma of hamsters during casein induction of AA-amyloidosis.

Authors:  P R Hol; A M van Ederen; F W Snel; J P Langeveld; J H Veerkamp; E Gruys
Journal:  Br J Exp Pathol       Date:  1985-06

8.  Inactivation of amyloid-enhancing factor (AEF): study on experimental murine AA amyloidosis.

Authors:  Masatoshi Omoto; Tadaaki Yokota; Dan Cui; Yoshinobu Hoshii; Hiroo Kawano; Toshikazu Gondo; Tokuhiro Ishihara; Takashi Kanda
Journal:  Med Mol Morphol       Date:  2007-06-18       Impact factor: 2.309

9.  A novel method for quantifying peripheral tissue amyloid load by using the radiolabeled amyloidophilic peptide, p5.

Authors:  Jonathan S Wall; Tina Richey; Sally Macy; Eric Heidel; Craig Wooliver; Stephen J Kennel
Journal:  Amyloid       Date:  2013-01-17       Impact factor: 7.141

10.  The failure of ascorbic acid therapy to alter the induction or remission of murine amyloidosis.

Authors:  M L Baltz; D Caspi; B E Glatthaar; U Moser; M B Pepys
Journal:  Clin Exp Immunol       Date:  1984-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.